Key clinical point: Renal function had no impact on idarucizumab’s efficacy for dabigatran reversal.
Major finding: Complete dabigatran reversal occurred in 98% of patients with severe renal dysfunction who received idarucizumab.
Study details: Post hoc analysis of data from RE-VERSE AD, idarucizumab’s pivotal trial with 503 patients.
Disclosures: RE-VERSE AD was funded by Boehringer Ingelheim, the company that markets idarucizumab (Praxbind) and dabigatran (Pradaxa). Dr. Eikelboom has been a consultant to and has received research support from Boehringer Ingelheim, as well as from Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, Janssen, and Pfizer.
Source: Eikelboom JW et al. ACC 18, the annual meeting of the American College of Cardiology, Abstract 1231M-11.
Eikelboom JW et al. ACC 18, the annual meeting of the American College of Cardiology, Abstract 1231M-11.
This Week's Must Reads
Improved myeloma outcomes associated with having prescription drug coverage, Olszewski A et al. J Clin Oncol. 2018 Aug 16. doi: 10.1200/JCO.2018.77.8894
For lymphoma patients, insurance is a matter of life or death , Goldstein JS et al. Blood. 2018 Jul 24. doi: 10.1182/blood-2018-03-839035
Concerns rise over proposal by CMS to level E/M payments , CMS proposed rule, CMS-1693-P
Expansion in clinical trial eligibility requested by ASCO, Friends of Cancer and ASCO letter to the FDA
Cleveland institutions to study CAR-T in Non-Hodgkin lymphoma, University Hospitals Cleveland Medical Center press statement
Must Reads in Bleeding Disorders
Avatrombopag reduces procedure-related transfusions in chronic liver disease and thrombocytopenia, Terrault N et al. Gastroenterology. 2018 May 17. doi: 10.1053/j.gastro.2018.05.025.
Prehospital plasma improves odds of survival in hemorrhagic shock, Sperry JL et al. N Engl J Med. 2018 Jul 26;379(4):315-26.
Thrombocytopenia in pregnancy raises risk of complications, Reese J et al. N Engl J Med. 2018;379:32-43.
Red cell tranfusion may increase risk of postsurgical VTE, Goel R et al. JAMA Surg. 2018 Jun 13. doi: 10.1001/jamasurg.2018.1565
Dapagliflozin suppresses hepcidin, boosts hematocrit, Ghanim HA et al. AACE 2018, Abstract 228.